For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

“But we didn’t know the exact role they play, or how they work to drive lung cancer progression. I think this study really ...

He added, "But we didn't know the exact role they play, or how they work to drive lung cancer progression. I think this study ...

Lung cancer is commonly diagnosed as small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). In America, lung ...

Five years later 60% of patients given lorlatinib were still alive without signs of disease progression, compared to 8% in ...

A flawed new algorithm for distributing lungs to transplant patients wound up putting people with Type O blood at a ...

A tracer known as FAPI performed better than the commonly used 18F-FDG for capturing early signs of pulmonary fibrosis on PET ...

What is the life expectancy of someone with interstitial lung disease? Answered by Dr. Howard E. Lewine M.D. Chief Medical ...

In 5-year follow-up data from the phase III CROWN trial of ALK -positive advanced non-small cell lung cancer (NSCLC), ...

AstraZeneca's (AZN) cancer therapy Tagrisso approved in China as a first-line treatment of lung cancer patients in ...

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® ...

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the ...